Satsuma Pharmaceuticals

$4.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.14 (+3.08%) Today
$0.00 (0.00%) As of 4:27 AM EST after-hours

Why Robinhood?

You can buy or sell STSA and other stocks, options, and ETFs commission-free!

About STSA

Satsuma Pharmaceuticals, Inc. Common Stock, also called Satsuma Pharmaceuticals, is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA. The listed name for STSA is Satsuma Pharmaceuticals, Inc. Common Stock.

CEO
John A. Kollins
Employees
17
Headquarters
San Francisco, California
Founded
2016
Market Cap
81.54M
Price-Earnings Ratio
Dividend Yield
Average Volume
383.30K
High Today
$4.85
Low Today
$4.54
Open Price
$4.60
Volume
353.74K
52 Week High
$36.11
52 Week Low
$3.50

Collections

STSA Earnings

-$2.26
-$1.51
-$0.75
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, After Hours

You May Also Like